shutterstock_309001163_bill_perry
Bill Perry / Shutterstock.com
10 August 2020Big PharmaMuireann Bolger

Teva wins appeal over thyroid drug at Fed Circuit

In a victory for  Teva Pharmaceuticals, the  US Court of Appeals for the Federal Circuit dismissed  IBSA Institut Biochimique’s appeal against a ruling that held parts of its patent invalid.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
14 February 2013   A US judge has declared pharmaceutical company Bristol-Myers Squibb’s patent covering its hepatitis B treatment Baraclude obvious and invalid.
Americas
15 January 2014   A US judge has said Teva Pharmaceuticals did not infringe patents belonging to a rival company after seeking approval to market a generic version of the drug.

More on this story

Americas
14 February 2013   A US judge has declared pharmaceutical company Bristol-Myers Squibb’s patent covering its hepatitis B treatment Baraclude obvious and invalid.
Americas
15 January 2014   A US judge has said Teva Pharmaceuticals did not infringe patents belonging to a rival company after seeking approval to market a generic version of the drug.

More on this story

Americas
14 February 2013   A US judge has declared pharmaceutical company Bristol-Myers Squibb’s patent covering its hepatitis B treatment Baraclude obvious and invalid.
Americas
15 January 2014   A US judge has said Teva Pharmaceuticals did not infringe patents belonging to a rival company after seeking approval to market a generic version of the drug.